American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6365)
  2. Solid Tumor Oncology Division (5506)
  3. Survivorship Research (1985)
  4. Genitourinary Oncology Service (1764)
  5. Surgery (1633)
  6. Epidemiology and Biostatistics (1481)
  7. GSK Faculty (1382)
  8. Population Sciences Research Program (1365)
  9. Gastrointestinal Oncology Service (1351)
  10. Hematologic Malignancies, Division of (1275)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2561)
  3. Editorial (73)
  4. Review (65)
  5. Guidelines (54)
  6. Correspondence (48)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6365)
  2. Solid Tumor Oncology Division (5506)
  3. Survivorship Research (1985)
  4. Genitourinary Oncology Service (1764)
  5. Surgery (1633)
  6. Epidemiology and Biostatistics (1481)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (250)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8678)
  2. JCO Precision Oncology (166)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (4)

More Publications

Results (9142)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported outcomes (PROs) in patients with ER+, HER2-advanced breast cancer (ABC) treated with imlunestrant, investigator's choice standard endocrine therapy, or imlunestrant plus abemaciclib: Results from the phase III EMBER-3 trial
    Meeting Abstract

    Curigliano, G.; O'Shaughnessy, J.; Bidard, F. C.; Kim, S. B.; Tokunaga, E.; Aftimos, P. G.; Manich, C. S.; Carey, L. A.; Okera, M.; Melo, E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) plus palbociclib (PALBO) plus fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2-), endocrine-resistant advanced breast cancer (aBC)
    Meeting Abstract

    Turner, N. C.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; Shankar, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2-LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts
    Meeting Abstract

    Oliveira, M.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Jhaveri, K. L.; Juric, D.; Kalinsky, K.; Krop, I. E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Obesity, chemotherapy dosing, and toxicity: Results from the Optimal Breast Cancer Chemotherapy Dosing study
    Meeting Abstract

    Kantor, E.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Doud, R. P.; Gallagher, G. B.; Griggs, J. J.; Monroy-Iglesias, M. J.; Kolevska, T.; Kroenke, C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Impact of initial chemotherapy dosing on subsequent dosing patterns and treatment completion in early-stage breast cancer
    Meeting Abstract

    Iglesias, M. J. M.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Doud, R. P.; Gallagher, G. B.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment-related neutropenia as a predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
    Meeting Abstract

    Fanucci, K.; Dueck, A. C.; Mayer, E. L.; Martin, M.; Haddad, T. C.; Zdenkowski, N.; Steger, G. G.; Novik, Y.; Suga, J. M.; Lemieux, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2-early breast cancer (EBC) eligible for NATALEE
    Meeting Abstract

    Abdou, Y.; Reid, S. A.; Jhaveri, K. L.; Pegram, M. D.; Schlam, I.; Sparano, J. A.; Olumba, B. T.; Santarsiero, E. C.; Ganapathy, V.; Akdere, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Performance evaluation of a reflex blood-based methylated ctDNA multi-cancer early detection test in individuals with obesity
    Meeting Abstract

    Kurbegov, D.; Massaad, E.; DiRienzo, A. G.; Withers, J. B.; Kashefhaghighi, D.; Charlton, J.; Sun, J.; Michor, F.; Chacko, K.; Pike, L. R. G.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms
    Meeting Abstract

    Cooper, A. J.; Chandana, S. R.; Furqan, M.; Papadopoulos, K. P.; Dowlati, A.; Han, J. Y.; Michael, M.; Cho, B. C.; Garmezy, B.; Kim, T. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Safety analyses from the phase III EMBER-3 trial
    Meeting Abstract

    O'Shaughnessy, J.; Bidard, F. C.; Neven, P.; Casalnuovo, M. L.; Aftimos, P. G.; Manich, C. S.; Harbeck, N.; Carey, L. A.; Curigliano, G.; García-Sáenz, J. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save